Exhibit 10.3

November 12, 2026
Sandesh Seth
100 Park Avenue, 23rd Floor
New York, NY 10017
Dear Mr. Seth:
On behalf of Actinium Pharmaceuticals, Inc. (the “Company”), I am pleased to provide you with this amended and restated contract (the “Agreement”) related to your position as Chief Executive Officer and Chairman of the Board of the Company. This Agreement replaces your employment agreement with the Company dated August 12, 2020, as amended on November 1, 2023 (the “Prior Agreement”). This Agreement sets forth the terms related to your position as Chief Executive Officer and Chairman of the Board of the Company.
1. Position. The terms of your position with the Company are as set forth below:
(a) You shall serve as Chief Executive Officer and Chairman of the Board of the Company with such responsibilities, duties and authority as are assigned to you by the Board of Directors (the “Board”), or its designee. These responsibilities shall include implementation of the overall direction of the Company as agreed to with the Board, including strategic planning, corporate policies, research and development, staffing, finance, commercial, business development and all aspects of company operations. You shall perform such other duties and shall have authority consistent with your position.
(b) You agree to devote your best efforts to advance the interests of the Company and to discharge adequately your duties hereunder. Nothing herein shall prohibit you from being an investor in another company such as a member of a limited liability company, a general or limited partner of a limited partnership or a stockholder of a corporation, or accepting or continuing in any advisory or board position with any other for-profit or non-profit entity, so long as such activities are not in direct competition with the Company’s business and do not interfere with the duties of your position with the Company.
2. Compensation. The Board shall review the amount of your base salary and performance bonus, and shall determine the appropriate adjustments to each component of your compensation each calendar year as specified below. As has been customary, the services of an independent compensation consultant shall be utilized to determine the relevant benchmark companies and provide the market data which the Board shall use as reference materials in setting compensation in addition to other parameters including overall company performance.
(a) Base Salary. Each calendar year the Board will review your base salary and make appropriate adjustments as needed and make its best efforts to accomplish such review within the first calendar quarter. In doing so, the Board will seek to adjust your base salary so that it is competitively aligned to a range between the 25th (twenty-fifth) and 75th (seventy-fifth) percentile of the relevant market data of Chief Executive Officer positions of similarly situated publicly traded biotech companies; provided, however, that such adjustment does not represent a reduction in base salary.
(b) Performance Bonus. You shall be entitled to participate in a Company annual bonus program for each calendar year of your employment period, which shall be established by the Board pursuant to which the Board shall award bonuses to you, based upon the achievement of written individual and corporate objectives such as the Board shall determine in consultation and agreement with you. Upon the attainment of such performance objectives, in addition to your salary, you shall be entitled to a cash bonus in an amount to be determined by the Board with a target of sixty-five percent (65%) of your annual base salary (or, if greater, the median target bonus percentage of chief executive officers in the Company’s peer group, as determined annually by the Board’s independent compensation consultant subject to review and approval by the Compensation Committee of the Board and the Board), as well as any multiplier that may be deemed appropriate taking into consideration individual contributions, overall company performance and other industry related benchmarks based on relevant benchmark companies and market data. Any such bonus shall be paid to you in the calendar year following the annual period for which the bonus relates, and the Board shall make its best efforts to determine, award, and have the Company pay out such bonus to you, if applicable, by March 15th of such calendar year.
(c) Stock Option Grant. From time to time the Board may grant you an option to purchase common shares of the Company (the “Grant”). Unless specified otherwise, the Grant shall be subject to the vesting schedule below.
(i) Stock Options. Such option will have an exercise price equal to the closing price of the Company’s common stock on the date of Board approval of the Grant, which is equal to fair market value as determined by the Board on the date of the grant (the “Grant Date”).
(ii) Vesting Schedule of the Grant. Two percent (2%) of the Grant shall vest each month from the Grant Date until fully vested in accordance with the provisions of the Company’s Amended and Restated 2013 Stock Plan and 2019 Stock Plan. The term of all options granted under this Agreement will be for 10 years from the Grant Date, subject to your continuing service with the Company. The options will be incentive stock options to the maximum extent allowed by the tax code and will be subject to the terms of the Company’s Amended and Restated 2013 Stock Plan and 2019 Stock Plan and corresponding Stock Option Agreement between you and the Company.
(iii) Change of Control. Notwithstanding anything to the contrary in any Company equity incentive plan or award agreement, any outstanding equity award granted to you that is not assumed or substituted with an equivalent award in a Change of Control shall become fully vested and exercisable immediately prior to the Change of Control, with any performance goals deemed satisfied at “target.” Awards that are assumed or substituted shall vest as provided in Sections 5(a)(iii) or 5(b)(iii). Nothing in this Agreement shall limit any more favorable vesting, exercisability or other treatment of your equity awards under any Company equity incentive plan or award agreement.
3. Benefits.
(a) Benefit Plans. The Company will provide you with the opportunity to participate in the standard benefits plans currently available to other senior executives, including health, disability and life insurance plans. The Company reserves the right to cancel and/or change the benefits plans it offers to its participants at any time, subject to applicable law.
(b) Vacation; Sick Leave. You will be entitled to 20 days paid vacation per year. Vacation may not be taken before it is accrued. You will be entitled to 5 days paid sick leave per year. You may carry over a maximum of 5 days of paid vacation days and 5 days of paid sick leave time in accordance with the Company’s vacation and sick leave policy.
(c) Reimbursement of Expenses. You shall be reimbursed for all normal items of travel and entertainment and miscellaneous expenses reasonably incurred by you on behalf of the Company provided such expenses are documented and submitted in accordance with the reimbursement policies in effect from time to time.
4. Confidential Information and Invention Assignment Agreement. Your continued employment is conditioned on your execution and compliance with the Company’s Confidential Information and Invention Assignment Agreement (the “Confidentiality Agreement”) attached hereto as Attachment A.
2
5. Term and Severance. The term of your Chief Executive Officer and Chairman of the Board positions shall be until February 21, 2030, unless terminated earlier as provided herein. If your employment as Chief Executive Officer or Chairman of the Board is terminated because of your death or Disability, the Company’s only obligation to you shall be to pay your earned, but unpaid, salary (as of the date of termination), benefits, the Pro-Rated Bonus (as defined below) for the year of termination and any Prior Year Bonus (as defined below), and to provide you, if eligible, with the option to elect health coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”); provided that upon termination of your employment due to death, your estate also shall be entitled to receive a single lump sum payment equal to three (3) months of your compensation (as defined in Section 5(i)), payable within 30 days of your death. Upon termination of your employment for Cause (as defined below), or your resignation without Good Reason (as defined below), you shall be paid any accrued and unpaid base salary, the Pro-Rated Bonus, any Prior Year Bonus and benefits through the date of termination and shall have no further rights to any compensation or any other benefits under this Agreement or otherwise.
(a) Termination of Service Other Than for Cause or Resignation for Good Reason (Not in Connection with a Change of Control). If the Company terminates your employment or Chairman position other than for Cause or Disability or death, or if you resign for Good Reason, in any case in circumstances other than those described in Section 5(b), you shall be entitled to the following:
(i) Subject to Section 6 hereof, a single lump sum payment equal to twenty-four (24) months of your compensation (as defined in Section 5(i)), payable on the first payroll date following the date the Release (as defined in Section 6 hereof) becomes effective and irrevocable in accordance with its terms.
(ii) Subject to Section 6 hereof, continued health benefits for the 24-month period beginning on the date of termination, with such period to run concurrently with any period for which you are eligible to elect health coverage under COBRA. During this continuation period, the Company will pay the full premiums for such coverage for you and your eligible dependents (or, if such payment is not permitted by law or COBRA coverage ends, an equal monthly taxable cash payment). If you begin providing services to another service recipient and become covered by such service recipient’s health benefits plan or program, the continued health benefits and Company payments provided hereunder shall cease.
(iii) Notwithstanding anything to the contrary in any Company equity incentive plan or award agreement, all outstanding equity awards granted to you under the Company’s equity compensation plans shall become immediately vested and exercisable (as applicable) as of the date of such termination, the performance goals with respect to such outstanding performance awards, if any, will be deemed satisfied at “target”, and all outstanding and vested Company stock options (including those that vest pursuant to the operation of this paragraph) will remain exercisable for the full duration of their term.
(iv) Subject to Section 6 hereof, a single lump sum payment equal to your Bonus Amount (as defined in Section 5(i)) for the year of termination, pro-rated based on the number of days you are employed or providing services in the Company’s fiscal year through (and including) the date of termination (the “Pro-Rated Bonus”), payable on the first payroll date following the date the Release (as defined in Section 6 hereof) becomes effective and irrevocable in accordance with its terms.
(b) Change of Control. If the Company terminates your employment or Chairman position other than for Cause or Disability or death, or if you resign for Good Reason, or if the Company fails to renew your position as Chief Executive Officer and Chairman of the Board on February 21, 2030 under this Agreement and your employment with the Company terminates, in any case during the period beginning on the date that is three (3) months prior to the date of a Change of Control and ending on the last day of the 24-month period beginning on the date of a Change of Control (as defined in the Company’s 2019 Stock Plan, as amended, or any successor equity plan) (the “Change of Control Period”), you shall be entitled to the following:
(i) Subject to Section 6 hereof, a single lump sum payment equal to thirty (30) months of your compensation (as defined in Section 5(i)), payable on the first payroll date following the date the Release (as defined in Section 6 hereof) becomes effective and irrevocable in accordance with its terms.
(ii) Subject to Section 6 hereof, continued health benefits for the 30-month period beginning on the date of termination, with such period to run concurrently with any period for which you are eligible to elect health coverage under COBRA. During this continuation period, the Company will pay the full premiums for such coverage for you and your eligible dependents (or, if such payment is not permitted by law or COBRA coverage ends, an equal monthly taxable cash payment). If you begin providing services to another service recipient and become covered by such service recipient’s health benefits plan or program, the continued health benefits and Company payments provided hereunder shall cease.
3
(iii) Notwithstanding anything to the contrary in any Company equity incentive plan or award agreement, all outstanding equity awards granted to you under the Company’s equity compensation plans shall become immediately vested and exercisable (as applicable) as of the date of such termination, the performance goals with respect to such outstanding performance awards, if any, will be deemed satisfied at “target”, and all outstanding and vested Company stock options (including those that vest pursuant to the operation of this paragraph) will remain exercisable for the full duration of their term.
(iv) Subject to Section 6 hereof, a single lump sum payment equal to the Pro-Rated Bonus, payable on the first payroll date following the date the Release (as defined in Section 6 hereof) becomes effective and irrevocable in accordance with its terms.
If your termination occurs during the Change of Control Period but before the Change of Control, the Company shall pay you the excess of the Section 5(b) payments and benefits over those provided under Section 5(a), in a lump sum within thirty (30) days after the Change of Control (or, if required by Section 409A, at the same time and in the same form as the Section 5(a) payments), and shall extend your health benefits to the full 30-month period.
(c) “Cause” means: (i) your gross negligence and/or willful misconduct (as such terms are generally understood and applied to the performance of an executive) in the performance of your material duties with respect to the Company as determined, in each case, by a court of competent jurisdiction not subject to further appeal or a final arbitration award, as provided hereunder; (ii) the conviction by you of a crime constituting a felony; or (iii) you shall have committed any material act of malfeasance, dishonesty or breach of fiduciary duty against the Company, for which you shall have a thirty (30) day cure period following notice thereof from the Company (except for a conviction pursuant to subsection (ii), for which there shall be no cure period). Except for a conviction pursuant to subsection (ii) herein, no termination shall be for Cause unless (A) you have been given written notice describing in reasonable detail the conduct alleged to constitute Cause, (B) you have been given an opportunity, together with counsel, to be heard before the Board, and (C) following such hearing and the expiration of any applicable cure period, the Board has determined, by the affirmative vote of not less than two-thirds (2/3) of the independent members of the Board (excluding you), that Cause exists.
(d) “Good Reason” means: (i) the Company’s material breach of any of its obligations under this Agreement; (ii) a material reduction of your base salary or target bonus opportunity; (iii) a material change to your title, reporting relationship, authority, duties or the scope of your work; (iv) an abandonment of, or fundamental change in, the primary business or primary products of the Company; (v) the termination or elimination of your duties as Chief Executive Officer or director or Chairman of the Board of the Company, other than for Cause or voluntary resignation; (vi) the appointment of a new Chief Executive Officer or Chairman of the Board, or person performing similar duties; (vii) the Company’s regular requirement that you perform services in or relocate to a location that is more than 25 miles outside of New York City; (viii) the failure of the Company to obtain the express written assumption of this Agreement by any successor or acquirer as required by Section 16; (ix) following a Change of Control, your ceasing to serve as the chief executive officer of the ultimate parent entity of the Company or its successor, reporting directly to the board of directors of such ultimate parent entity; (x) the failure of the Board to nominate you for election or re-election as a director of the Company; or (xi) any requirement that you report to anyone other than the Board. A termination will not be deemed to be for Good Reason unless the Company does not cure within 30 days after receipt of written notice from you specifying the Good Reason and referring to your right to resign for Good Reason. Any resignation for Good Reason will be effective immediately upon your giving notice of your resignation for Good Reason to the Company, conditioned upon your having provided proper notice of Good Reason and time to cure in accordance with this provision.
(e) “Disability” means that (i) you have been unable, for a period of 180 consecutive business days, to perform your duties under this Agreement, as a result of physical or mental illness or injury, and (ii) a physician selected or approved by the Company has determined that it is either not possible to determine when such inability to perform will cease or that it appears probable that such inability will be permanent during the remainder of your life.
(f) Mitigation. In the event that you are entitled to severance pursuant to this Agreement, you have no duty to mitigate and your severance will not be reduced for any reason. The Company’s obligation to make the payments and provide the benefits under this Agreement shall not be subject to any set-off, counterclaim, recoupment, defense or other claim the Company may have against you, except as required by applicable law or by the Company’s clawback policy adopted to comply with Rule 10D-1 under the Securities Exchange Act of 1934, as amended.
4
(g) Prior Year Bonus. “Prior Year Bonus” means any unpaid annual bonus under Section 2(b) for the calendar year before the year of your termination, based on actual performance as determined by the Board or, if not yet determined, no less than the greater of your target bonus for that year and your average actual bonus for the three (3) preceding years. It is earned compensation, payable on termination for any reason without regard to Section 6, in a lump sum on the later of the first payroll date after termination and the date such bonuses are paid to other senior executives, and in all events within the Section 409A short-term deferral period.
(h) Non-Renewal. “Non-Renewal” means the Company’s failure, by August 21, 2029, to offer you in writing an extension of your term as Chief Executive Officer and Chairman of the Board on terms (including position, duties, reporting, compensation and severance) no less favorable than this Agreement. A termination following a Non-Renewal on or after February 21, 2030 (or earlier at the Company’s election) shall be treated as a termination other than for Cause under Section 5(a) or, during the Change of Control Period, Section 5(b).
(i) Compensation. Your monthly “compensation” means one-twelfth of your annual base salary plus your Bonus Amount, each at the highest rate in effect during the twelve (12) months before your termination (or, for a termination under Section 5(b), immediately before the Change of Control, if higher). “Bonus Amount” means the greater of your highest target annual bonus during those twelve (12) months and your average actual annual bonus (including any discretionary Board multiplier of such annual bonus) for the three (3) calendar years before the year of your termination. Payments under Sections 5(a)(i) or 5(b)(i) are in addition to the Pro-Rated Bonus, any Prior Year Bonus and the equity vesting under Sections 5(a)(iii) or 5(b)(iii).
(j) Accrued Obligations. Notwithstanding anything else in this Section 5, on any termination you (or your estate) shall receive earned but unpaid base salary and accrued but unused vacation (paid by the next regular payroll date), reimbursement of business expenses under Section 3(c), and vested benefits under the Company’s benefit plans in accordance with their terms.
6. Release. Notwithstanding anything contained herein to the contrary, the Company shall not be obligated to provide any severance payment or benefit under Sections 5(a)(i), 5(a)(ii), 5(a)(iv), 5(b)(i), 5(b)(ii), or 5(b)(iv) hereof unless: (a) you or your legal representative first executes within 50 calendar days after the date of presentment a release of claims agreement in the form as to be provided by the Company (the “Release”) and substantially similar to the form of Release attached hereto as Attachment B, which shall impose no obligations or restrictive covenants not in this Agreement and shall include the Company’s release of all claims against you (other than for fraud or willful misconduct), (b) you do not revoke the Release, and (c) the Release becomes effective and irrevocable in accordance with its terms. The Company shall provide the Release to you for your review within ten (10) days of the date of termination.
7. Non-Solicitation. You agree that during the term of your employment with the Company, and for a period of 24 months following the cessation of employment with the Company for any reason or no reason, you shall not directly or indirectly solicit, induce, recruit or encourage any of the Company’s employees or consultants to terminate their relationship with the Company, or attempt any of the foregoing, either for yourself or any other person or entity. For a period of 24 months following cessation of your employment with the Company for any reason or no reason, you shall not attempt to negatively influence any of the Company’s clients or customers from purchasing Company products or services or to solicit or influence or attempt to influence any client, customer or other person either directly or indirectly, to direct his or its purchase of products and/or services to any person, firm, corporation, institution or other entity in competition with the business of the Company.
8. Arbitration. Any dispute or claim arising out of or in connection with your employment with the Company (except with regard to enforcement of the Confidentiality Agreement) will be finally settled by arbitration in New York, New York in accordance with the Commercial Arbitration Rules of the American Arbitration Association by one arbitrator appointed in accordance with said rules. Judgment on the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. The parties agree that this Agreement evidences a transaction involving interstate commerce and that the operation, interpretation and enforcement of this arbitration provision, the procedures to be used in conducting an arbitration pursuant to this arbitration provision, and the confirmation of any award issued to either party by reason of such arbitration, is governed exclusively by the Federal Arbitration Act, 9 U.S.C. § 1 et seq. Notwithstanding the foregoing, the parties may apply to any court of competent jurisdiction for preliminary or interim equitable relief, or to compel arbitration in accordance with this paragraph, without breach of this arbitration provision. The Company shall pay all fees and expenses for the arbitration itself. The Company will pay your reasonable legal fees as incurred, within thirty (30) days following submission of invoices therefor, provided that, if you substantially do not prevail, the Company shall be reimbursed for your reasonable legal fees.
5
9. Indemnification. Effective August 7, 2015, you entered into an Indemnification Agreement with the Company (the “Indemnification Agreement”). The Indemnification Agreement shall remain in effect. In addition, the Company shall maintain directors’ and officers’ liability insurance covering you during your employment and for not less than six (6) years thereafter, on terms no less favorable than those provided to the Company’s other directors and officers, and, in connection with a Change of Control, shall obtain (or cause the acquirer to obtain) a six (6) year “tail” policy covering you.
10. Section 280G. In the event it shall be determined that any payment or distribution by the Company to or for your benefit (whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise) (the “Total Payments”) is or will be subject to the excise tax (the “Excise Tax”) imposed by Section 4999 of the Internal Revenue Code of 1986, as amended (the “Code”), then the Total Payments shall be reduced to the maximum amount that could be paid to you without giving rise to the Excise Tax (the “Safe Harbor Cap”), if the net after-tax benefit to you after reducing your Total Payments to the Safe Harbor Cap is greater than the net after-tax (including the Excise Tax) benefit to you without such reduction. The reduction of the amounts payable hereunder, if applicable, shall be made by reducing such payments that trigger the Excise Tax in the following order: (i) reduction of cash payments, (ii) cancellation of accelerated vesting of performance-based equity awards (based on the reverse order of the date of grant), (iii) cancellation of accelerated vesting of other equity awards (based on the reverse order of the date of grant), and (iv) reduction of any other payments due to you (with benefits or payments in any group having different payment terms being reduced on a pro-rata basis). All mathematical determinations, and all determinations as to whether any of the Total Payments are “parachute payments” (within the meaning of Section 280G of the Code), that are required to be made under this paragraph, including determinations as to whether the Total Payments to you shall be reduced to the Safe Harbor Cap and the assumptions to be utilized in arriving at such determinations, shall be made at the Company’s expense by the Company’s then current independent auditors, or such other nationally recognized accounting firm selected by the Compensation Committee of the Board prior to the relevant change of control transaction. The independent auditors or accounting firm, as applicable, shall, at the Company’s expense, do a valuation of your obligations under Sections 4 and 7 and any other non-competition or non-solicitation agreements or provisions executed by you in favor of the Company, to be used, if necessary, to minimize or eliminate the need to reduce any Total Payments.
11. Section 409A.
(a) In General. It is the Company’s intent that this Agreement be exempt from the application of, or otherwise comply with, the requirements of Section 409A of the Code (“Section 409A”). Specifically, any taxable benefits or payments provided under this Agreement are intended to be separate payments that qualify for the “short-term deferral” exception to Section 409A to the maximum extent possible, and to the extent they do not so qualify, are intended to qualify for the involuntary separation pay exceptions to Section 409A, to the maximum extent possible. If neither of these exceptions applies, and if you are a “specified employee” within the meaning of Section 409A, then notwithstanding any provision in this Agreement to the contrary and to the extent required to comply with Section 409A, all amounts that would otherwise be paid or provided to you during the first six (6) months following your date of termination shall instead be accumulated through and paid or provided (without interest) on the first business day following the six-month anniversary of the date of termination. If the period during which the Release must become effective and irrevocable in accordance with its terms spans two calendar years, then, to the extent required to comply with Section 409A, any payment to be made under this Agreement will commence on the first payroll date that occurs in the second calendar year and after the Release has become effective and irrevocable in accordance with its terms. Further, to the extent required to comply with Section 409A: (i) the amount of any expense reimbursement to which you may be entitled hereunder during a calendar year will not affect the amount of reimbursements to be provided in any other calendar year; (ii) your right to receive reimbursement of an eligible expense hereunder is not subject to liquidation or exchange for another benefit; and (iii) provided that the requisite documentation is submitted, the Company will reimburse your eligible expenses on or before the last day of the calendar year following the calendar year in which the expense was incurred. If under this Agreement an amount is paid in two (2) or more installments, for purposes of Section 409A, each installment will be treated as a separate and distinct payment. All severance benefits will be completed by, and no further severance benefits will be payable after, December 31 of the second taxable year following the year in which your termination of employment occurs, other than the continued health benefits under Sections 5(a)(ii) and 5(b)(ii), which shall be provided for the full period specified therein in a manner that complies with, or is exempt from, Section 409A.
6
(b) Separation from Service. A termination of service shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits subject to Section 409A upon or following a termination of service unless such termination is also a “separation from service” within the meaning of Section 409A and you are no longer providing services (at a level that would preclude the occurrence of a “separation from service” within the meaning of Section 409A) to the Company or its affiliates as an employee or consultant, and for purposes of any such provision of this Agreement, references to a “termination,” “termination of employment” or like terms shall mean “separation from service” within the meaning of Section 409A.
12. Attorneys’ Fees. Subject to Section 8, should either party hereto, or any heir, personal representative, successor or assign of either party hereto, resort to legal proceedings in connection with this Agreement, the party or parties prevailing in such legal proceedings shall be entitled, in addition to such other relief as may be granted, to recover its or their reasonable attorneys’ fees and costs in such legal proceedings from the non-prevailing party or parties.
13. Assistance in Litigation. You shall, during and after termination of employment, upon reasonable notice, furnish such information and proper assistance to the Company as may reasonably be required by the Company in connection with any litigation in which it or any of its subsidiaries or affiliates is, or may become, a party; provided, however, that such assistance following termination shall be furnished at mutually agreeable times and for mutually agreeable compensation.
14. Miscellaneous. This Agreement, together with the Confidentiality Agreement and Indemnification Agreement, sets forth the terms of your employment with the Company and supersedes any prior representations or agreements, whether written or oral, including, without limitation, the Prior Agreement. This Agreement may not be modified or amended except by a written agreement, signed by the Company and by you. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will be lessened or reduced to the extent possible or will be severed and will not affect any other provision and this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein. This Agreement will be governed by New York law without reference to rules of conflicts of law. All notices, requests, demands and other communications called for hereunder shall be in writing and shall be deemed given (i) on the date of delivery if delivered personally, (ii) one (1) day after being sent by a well-established commercial overnight service, (iii) three (3) days after being mailed by registered or certified mail, return receipt requested, prepaid and addressed to the parties or their successors at the following addresses, or at such other addresses as the parties may later designate in writing, (iv) upon confirmation of facsimile transfer, if sent by facsimile or (v) upon confirmation of delivery when directed to the electronic mail address set forth below, if sent by electronic mail:
| If to the Company: | 100 Park Ave 23rd Floor New York, NY 10017 | |
| If to you: | 100 Park Avenue, 23rd Floor New York, NY 10017 |
15. Withholding of Taxes. The Company may withhold from any amounts payable under this Agreement all federal, state, city or other taxes as the Company may be required to withhold pursuant to any law or government regulation or ruling.
16. Successors and Assigns. This Agreement binds and benefits the Company and its successors and assigns, and you and your heirs and legal representatives. The Company shall require any direct or indirect successor to all or substantially all of its business or assets, and any acquirer in a Change of Control (including its ultimate parent), to expressly assume this Agreement in writing, and “Company” includes any such successor. You may not assign this Agreement other than by will or the laws of descent and distribution.
17. Survival. Sections 4 through 16 of this Agreement, and any other provisions of this Agreement that by their terms are to be performed or have effect after the expiration of the term or the termination of your employment, shall survive the expiration of the term and any termination of your employment.
[Signature Page Follows]
7
To indicate your acceptance of the Agreement, please sign and date this Agreement in the space provided below and return it to the Company.
| Very truly yours, | ACCEPTED AND AGREED: | ||
| ACTINIUM PHARMACEUTICALS, INC. | SANDESH SETH | ||
| By: | /s/ David Nicholson | /s/ Sandesh Seth | |
| David Nicholson | Sandesh Seth | ||
| Chairman, Compensation Committee | |||
8
ATTACHMENT A
Actinium Pharmaceuticals, Inc.
CONFIDENTIAL INFORMATION AND INVENTION ASSIGNMENT AGREEMENT
As a condition of my becoming employed by Actinium Pharmaceuticals, Inc., a Delaware corporation, or any of its current or future subsidiaries, affiliates, successors or assigns (collectively, the “Company”), and in consideration of my employment with the Company and my receipt of the compensation now and hereafter paid to me by the Company, I agree to the following:
1. Employment Relationship. I understand and acknowledge that this Agreement does not alter, amend or expand upon any rights I may have to continue in the employ of, or the duration of my employment relationship with, the Company under any existing agreements between the Company and me or under applicable law. Any employment relationship between the Company and me, whether commenced prior to or upon the date of this Agreement, shall be referred to herein as the “Relationship.”
2. Duties. I will perform for the Company such duties as may be designated by the Company from time to time. During the Relationship, I will devote my best efforts to the interests of the Company and will not engage in other employment or in any activities detrimental to the best interests of the Company without the prior written consent of the Company.
3. At-Will Relationship. I understand and acknowledge that my Relationship with the Company is and shall continue to be at-will, as defined under applicable law, meaning that either I or the Company may terminate the Relationship at any time for any reason or no reason, without further obligation or liability.
4. Confidential Information.
(a) Company Information. I agree at all times during the term of my Relationship with the Company and thereafter for 24 months, to hold in strictest confidence, and not to use, except for the benefit of the Company to the extent necessary to perform my obligations to the Company under the Relationship, or to disclose to any person, firm, corporation or other entity without written authorization of the Board of Directors of the Company, any Confidential Information of the Company which I obtain or create. I further agree not to make copies of such Confidential Information except as authorized by the Company. I understand that “Confidential Information” means any Company proprietary information, technical data, trade secrets or know-how, including, but not limited to, research, product plans, products, services, suppliers, customer lists and customers (including, but not limited to, customers of the Company on whom I called or with whom I became acquainted during the Relationship), prices and costs, markets, software, developments, inventions, laboratory notebooks, processes, formulas, technology, designs, drawings, engineering, hardware configuration information, marketing, licenses, finances, budgets or other business information disclosed to me by the Company either directly or indirectly in writing, orally or by drawings or observation of parts or equipment or created by me during the period of the Relationship, whether or not during working hours. I understand that “Confidential Information” includes, but is not limited to, information pertaining to any aspects of the Company’s business which is either information not known by actual or potential competitors of the Company or other third parties not under confidentiality obligations to the Company, or is otherwise proprietary information of the Company or its customers or suppliers, whether of a technical nature or otherwise. I further understand that Confidential Information does not include any information which has become publicly known and made generally available through no wrongful act of mine, was known to me at the time it was disclosed, is lawfully and in good faith made available to me by a third party who did not derive it, directly or indirectly, from the Company, or is information that is independently discovered or developed by me without violating my obligations under this Agreement and which can be demonstrated by competent evidence.
(b) Prior Obligations. I represent that my performance of all terms of this Agreement as an employee of the Company has not breached and will not breach any agreement to keep in confidence information acquired by me prior or subsequent to the commencement of my Relationship with the Company, and I will not disclose to the Company or use any inventions, confidential or non-public proprietary information or material belonging to any previous client, employer or any other party. I will not induce the Company to use any inventions, confidential or non-public proprietary information or material belonging to any previous client, employer or any other party. I acknowledge and agree that I have in good faith listed on Exhibit B all agreements (e.g., non-competition agreements, non-solicitation of customers agreements, non-solicitation of employees agreements, confidentiality agreements, inventions agreements, etc.) with a current or former employer, or any other person or entity, that may reasonably restrict my ability to recruit or engage customers or service providers on behalf of the Company, or otherwise relate to or restrict my ability to perform my duties as an employee of the Company or any obligation I may have to the Company.
9
(c) Third Party Information. I recognize that the Company has received and in the future will receive confidential or proprietary information from third parties subject to a duty on the Company’s part to maintain the confidentiality of such information and to use it only for certain limited purposes. I agree to hold all such confidential or proprietary information in the strictest confidence and not to disclose it to any person, firm or corporation or to use it except as necessary in carrying out my work for the Company consistent with the Company’s agreement with such third party.
5. Inventions.
(a) Inventions Retained and Licensed. I have in good faith and to the best of my knowledge attached hereto, as Exhibit A, a list describing with particularity all inventions, original works of authorship, developments, improvements, and trade secrets which were made by me prior to the commencement of the Relationship (collectively referred to as “Prior Inventions”), which belong solely to me or belong to me jointly with another, which as of the execution of this Agreement may reasonably relate in any way to any of the Company’s proposed businesses, products or research and development, and which are not assigned to the Company hereunder; or, if no such list is attached, I represent that there are no such Prior Inventions. If, in the course of my Relationship with the Company, I incorporate into a Company product, process or machine a Prior Invention owned by me or in which I have an interest, the Company is hereby granted and shall have a non-exclusive, royalty-free, irrevocable, perpetual, worldwide license (with the right to sublicense) to make, have made, copy, modify, make derivative works of, use, sell and otherwise distribute such Prior Invention as part of or in connection with such product, process or machine.
(b) Assignment of Inventions. I agree that I will promptly make full written disclosure to Company, will hold in trust for the sole right and benefit of the Company, and hereby assign to Company, or its designee, all my right, title and interest throughout the world in and to any and all inventions related to the Company’s technology or development programs as currently operated or contemplated, original works of authorship, developments, concepts, know-how, improvements or trade secrets, whether or not patentable or registrable under copyright or similar laws, which I may solely or jointly conceive or develop or reduce to practice, or cause to be conceived or developed or reduced to practice, during the period of time in which I am employed by the Company (collectively referred to as “Inventions”), except as provided in Exhibit A. I further acknowledge that all inventions, original works of authorship, developments, concepts, know-how, improvements or trade secrets which are made by me (solely or jointly with others) within the scope of and directly related to Company’s technology or development programs as currently operated or contemplated and during the period of my Relationship with the Company are “works made for hire” (to the greatest extent permitted by applicable law) and are compensated by my salary (if I am an employee), unless regulated otherwise by the mandatory law of the State of New York.
(c) Maintenance of Records. I agree to keep and maintain adequate and current written records of all Inventions made by me (solely or jointly with others) during the term of my Relationship with the Company. The records may be in the form of notes, sketches, drawings, flow charts, electronic data or recordings, laboratory notebooks, and any other format. The records will be available to and remain the sole property of the Company at all times. I agree not to remove such records from the Company’s place of business except as expressly permitted by Company policy which may, from time to time, be revised at the sole election of the Company for the purpose of furthering the Company’s business. I agree to return all such records (including any copies thereof) to Company at the time of termination of my Relationship with the Company as provided for in Section 6.
10
(d) Patent and Copyright Rights. I agree to assist Company, or its designee, at its expense, in every proper way to secure Company, or its designee’s, rights in the Inventions and any copyrights, patents, trademarks, mask work rights, moral rights, or other intellectual property rights relating thereto in any and all countries, including the disclosure to Company, or its designee, of all pertinent information and data with respect thereto, the execution of all applications, specifications, oaths, assignments, recordations, and all other instruments which Company or its designee shall deem necessary in order to apply for, obtain, maintain and transfer such rights and in order to assign and convey to Company or its designee and any successors, assigns and nominees the sole and exclusive rights, title and interest in and to such Inventions, and any copyrights, patents, mask work rights or other intellectual property rights relating thereto. I further agree that my obligation to execute or cause to be executed, when it is in my power to do so, any such instrument or papers shall continue after the termination of this Agreement until the expiration of the last such intellectual property right to expire in any country of the world. If the Company or its designee is unable because of my mental or physical incapacity or unavailability or for any other reason to secure my signature to apply for or to pursue any application for any United States or foreign patents, copyright, mask works, or other registrations covering Inventions or original works of authorship assigned to Company or its designee as above, then I hereby irrevocably designate and appoint Company and its duly authorized officers and agents as my agent and attorney-in-fact, to act for and in my behalf and stead to execute and file any such applications and to do all other lawfully permitted acts to further the application for, prosecution, issuance, maintenance or transfer of letters patent, copyright or other registrations thereon with the same legal force and effect as if originally executed by me. I hereby waive and irrevocably quitclaim to Company or its designee any and all claims, which I now or hereafter have for infringement of any and all proprietary rights assigned to Company or such designee.
6. Company Property; Returning Company Documents. I acknowledge and agree that I have no expectation of privacy with respect to the Company’s telecommunications, networking or information processing systems (including, without limitation, stored company files, e-mail messages and voice messages) and that my activity and any files or messages on or using any of those systems may be monitored at any time without notice. I further agree that any property situated on the Company’s premises and owned by the Company, including disks and other storage media, filing cabinets or other work areas, is subject to inspection by Company personnel at any time with or without notice. I agree that, at the time of termination of my Relationship with the Company, I will deliver to the Company (and will not keep in my possession, recreate or deliver to anyone else) any and all devices, records, data, notes, reports, proposals, lists, correspondence, specifications, drawings, blueprints, sketches, laboratory notebooks, materials, flow charts, equipment, other documents or property, or reproductions of any of the aforementioned items, developed by me pursuant to the Relationship or otherwise belonging to the Company, its successors or assigns. In the event of the termination of the Relationship, I agree to sign and deliver the “Termination Certification” attached hereto as Exhibit C; however, my failure to sign and deliver the Termination Certification shall in no way diminish my continuing obligations under this Agreement.
7. Notification to Other Parties.
(a) Employees. In the event that I leave the employ of the Company, I hereby consent to notification by the Company to my new employer about my rights and obligations under this Agreement.
(b) Consultants. I hereby grant consent to notification by the Company to any other parties besides the Company with whom I maintain a consulting or employment relationship, including parties with whom such relationship commences after the effective date of this Agreement, about my rights and obligations under this Agreement.
8. Solicitation of Employees, Consultants and Other Parties. I agree that during the term of my Relationship with the Company, and for a period of twenty-four (24) months immediately following the termination of my Relationship with the Company for any reason, whether with or without cause, I shall not either directly or indirectly solicit, induce, recruit or encourage any of the Company’s employees or consultants to terminate their relationship with the Company, or attempt to solicit, induce, recruit, encourage or take away employees or consultants of the Company, either for myself or for any other person or entity. Further, during my Relationship with the Company and at any time following termination of my Relationship with the Company for any reason, with or without cause, I shall not use any Confidential Information of the Company to attempt to negatively influence any of the Company’s clients or customers from purchasing Company products or services or to solicit or influence or attempt to influence any client, customer or other person either directly or indirectly, to direct his or its purchase of products and/or services to any person, firm, corporation, institution or other entity in competition with the business of the Company.
11
9. Representations and Covenants.
(a) Facilitation of Agreement. I agree to execute promptly any proper oath or verify any proper document required to carry out the terms of this Agreement upon the Company’s written request to do so.
(b) Conflicts. I knowingly represent that my performance of all the terms of this Agreement does not and will not breach any agreement I have entered into, or will enter into, with any third party, including without limitation any agreement to keep in confidence proprietary information acquired by me in confidence or in trust prior to commencement of my Relationship with the Company. I agree not to enter into any written or oral agreement that conflicts with the provisions of this Agreement.
(c) Voluntary Execution. I certify and acknowledge that I have carefully read all of the provisions of this Agreement and that I understand and will fully and faithfully comply with such provisions.
10. General Provisions.
(a) Governing Law. The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the State of New York, without giving effect to the principles of conflict of laws.
(b) Entire Agreement. This Agreement sets forth the entire agreement and understanding between the Company and me relating to the subject matter herein and merges all prior discussions between us. No modification or amendment to this Agreement, nor any waiver of any rights under this Agreement, will be effective unless in writing signed by both parties. Any subsequent change or changes in my duties, obligations, rights or compensation will not affect the validity or scope of this Agreement.
(c) Severability. If one or more of the provisions in this Agreement are deemed void by law, then the remaining provisions will continue in full force and effect.
(d) Successors and Assigns. This Agreement will be binding upon my heirs, executors, administrators and other legal representatives, and my successors and assigns, including any successor entity, and will be for the benefit of the Company, its successors, and its assigns.
(e) Survival. The provisions of this Agreement shall survive the termination of the Relationship and the assignment of this Agreement by the Company to any successor in interest or other assignee.
(f) Remedies. I acknowledge and agree that violation of this Agreement by me may cause the Company irreparable harm, and therefore agree that the Company will be entitled to seek relief in court, including but not limited to temporary restraining orders, preliminary injunctions and permanent injunctions without the necessity of posting a bond or other security and in addition to and without prejudice to any other rights and remedies that the Company may have for a breach of this Agreement.
(g) ADVICE OF COUNSEL. I ACKNOWLEDGE THAT, IN EXECUTING THIS AGREEMENT, I HAVE HAD THE OPPORTUNITY TO SEEK THE ADVICE OF INDEPENDENT LEGAL COUNSEL, AND I HAVE READ AND UNDERSTOOD ALL OF THE TERMS AND PROVISIONS OF THIS AGREEMENT. THIS AGREEMENT SHALL NOT BE CONSTRUED AGAINST ANY PARTY BY REASON OF THE DRAFTING OR PREPARATION HEREOF.
[Signature Page Follows]
12
The parties have executed this Confidential Information and Invention Assignment Agreement on the respective dates set forth below:
| COMPANY: | EMPLOYEE: | |||
| ACTINIUM PHARMACEUTICALS, INC. | ||||
| By: | /s/ David Nicholson | Signature: | /s/ Sandesh Seth | |
| Name: | David Nicholson | |||
| Title: | Chairman, Compensation Committee | Date: | November 13, 2026 | |
| Date: | November 13, 2026 | |||
13
EXHIBIT A
LIST OF PRIOR INVENTIONS AND ORIGINAL WORKS OF AUTHORSHIP
EXCLUDED UNDER SECTION 5
______ No inventions or improvements
______ Additional Sheets Attached
| Signature of Employee: | /s/ Sandesh Seth | |
| Print Name of Employee: | Sandesh Seth |
| Date: | November 13, 2026 |
EXHIBIT B
LIST OF PRIOR AGREEMENTS
| Name of Agreement | Parties to Agreement | Restriction(s) |
| Employee’s Signature: | /s/ Sandesh Seth |
| Date: | November 13, 2026 |
EXHIBIT C
TERMINATION CERTIFICATION
This is to certify that I do not have in my possession, nor have I failed to return, any devices, records, data, notes, reports, proposals, lists, correspondence, specifications, drawings, blueprints, sketches, laboratory notebooks, flow charts, materials, equipment, other documents or property, or copies or reproductions of any aforementioned items belonging to Actinium Pharmaceuticals, Inc., its subsidiaries, affiliates, successors or assigns (together the “Company”).
I further certify that I have complied with all the terms of the Company’s Confidential Information and Invention Assignment Agreement signed by me, including the reporting of any inventions and original works of authorship (as defined therein), conceived or made by me (solely or jointly with others) covered by that agreement.
I further agree that, in compliance with the Confidential Information and Invention Assignment Agreement, I will preserve as confidential all trade secrets, confidential knowledge, data or other proprietary information relating to products, processes, know-how, designs, formulas, developmental or experimental work, computer programs, data bases, other original works of authorship, customer lists, business plans, financial information or other subject matter pertaining to any business of the Company or any of its employees, clients, consultants or licensees.
I further agree that for twenty-four (24) months from the date of this Certification, I shall not either directly or indirectly solicit, induce, recruit or encourage any of the Company’s employees or consultants to terminate their relationship with the Company, or attempt to solicit, induce, recruit, encourage or take away, hire, or otherwise engage the services of employees or consultants of the Company, either for myself or for any other person or entity. Further, I shall not at any time use any Confidential Information of the Company to negatively influence any of the Company’s clients or customers from purchasing Company products or services or to solicit or influence or attempt to influence any client, customer or other person either directly or indirectly, to direct his or its purchase of products and/or services to any person, firm, corporation, institution or other entity in competition with the business of the Company.
| Date: | |||
| (Employee’s Signature) | |||
| (Type/Print Employee’s Name) |
ATTACHMENT B
RELEASE OF CLAIMS
FOR AND IN CONSIDERATION OF the payments and benefits (the “Separation Benefits”) to be provided to me in connection with the separation of my relationship with the Company, in accordance with the Amended and Restated Employment Agreement between Actinium Pharmaceuticals, Inc. (the “Company”) and me dated as of November 12, 2026 (the “Agreement”), which Separation Benefits are conditioned on my signing this Release of Claims (“Release”) and which I will forfeit unless I execute and do not revoke this Release of Claims, I, on my own behalf and on behalf of my heirs and estate, voluntarily, knowingly and willingly release and forever discharge the Company, its subsidiaries, affiliates, parents, and stockholders, together with each of those entities’ respective officers, directors, stockholders, employees, agents, fiduciaries and administrators (collectively, the “Releasees”) from any and all claims and rights of any nature whatsoever which I now have against them up to the date I execute this Release, whether known or unknown, suspected or unsuspected. This Release includes, but is not limited to, any rights or claims relating in any way to my employment or consulting relationship with the Company or any of the other Releasees or the termination thereof, any contract claims (express or implied, written or oral), including, but not limited to, the Agreement, or any rights or claims under any statute, including, without limitation, the Americans with Disabilities Act, the Age Discrimination in Employment Act, the Older Workers Benefit Protection Act, the Rehabilitation Act of 1973 (including Section 504 thereof), Title VII of the 1964 Civil Rights Act, the Civil Rights Act of 1866 (42 U.S.C. § 1981), the Civil Rights Act of 1991, the Equal Pay Act, the National Labor Relations Act, the Worker Adjustment and Retraining Notification Act, the Family and Medical Leave Act, the Lilly Ledbetter Fair Pay Act, the Genetic Information Nondiscrimination Act, the New York State Human Rights Law, the New York City Human Rights Law, and the Employee Retirement Income Security Act of 1974, all as amended, and any other federal, state or local law. This Release specifically includes, but is not limited to, any claims based upon the right to the payment of wages, incentive and performance compensation, bonuses, equity grants, vacation, pension benefits, 401(k) Plan benefits, stock benefits or any other employee benefits, or any other rights arising under federal, state or local laws prohibiting discrimination and/or harassment on the basis of race, color, age, religion, sexual orientation, religious creed, sex, national origin, ancestry, alienage, citizenship, nationality, mental or physical disability, denial of family and medical care leave, medical condition (including cancer and genetic characteristics), marital status, military status, gender identity, harassment or any other basis prohibited by law.
As a condition of the Company entering into this Release, I further represent that I have not filed against the Company or any of the other Releasees, any complaints, claims or lawsuits with any arbitral tribunal, administrative agency, or court prior to the date hereof, and that I have not transferred to any other person any such complaints, claims or lawsuits. I understand that by signing this Release, I waive my right to any monetary recovery in connection with a local, state or federal governmental agency proceeding and I waive my right to file a claim seeking monetary damages in any arbitral tribunal, administrative agency, or court. This Release does not: (i) prohibit or restrict me from communicating, providing relevant information to or otherwise cooperating with the U.S. Equal Employment Opportunity Commission or any other governmental authority with responsibility for the administration of fair employment practices laws or other governmental or law enforcement agency or entity (including, without limitation, the Securities and Exchange Commission) regarding a possible violation of such laws or responding to any inquiry from such authority, including an inquiry about the existence of this Release or its underlying facts, or (ii) require me to notify the Company of such communications or inquiry. Furthermore, notwithstanding the foregoing, this Release does not include and will not preclude: (a) rights or claims to vested benefits under any applicable retirement and/or pension plans; (b) rights under the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”); (c) claims for unemployment compensation; (d) rights to defense and indemnification, if any, from the Company for actions or inactions taken by me in the course and scope of my employment with the Company and its parents, subsidiaries and/or affiliates; (e) any rights I may have to obtain contribution as permitted by law in the event of entry of judgment against the Company as a result of any act or failure to act for which I and the Company are held jointly liable; (f) the right to any equity awards that vested prior to or because of the termination of my employment; (g) the right to any whistleblower award pursuant to Section 21F of the Securities Exchange Act of 1934 or any other similar provision; and/or (h) any actions to enforce the Agreement.
Nothing herein shall be construed to limit my right to (1) respond accurately and fully to any question, inquiry or request for information when required by legal process; or (2) disclose information to regulatory bodies. I understand that I am not required to contact the Company before engaging in such communications.
I acknowledge that, in signing this Release, I have not relied on any promises or representations, express or implied, other than those that are set forth expressly herein or in the Agreement and that are intended to survive separation from employment, in accordance with the terms of the Agreement.
I further acknowledge that:
1. I received this Release from the Company following my termination of employment in accordance with Section 6 of the Agreement;
2. I understand that, in order for this Release to be effective, I may not sign it prior to the date of my separation of employment with the Company but that if I wish to receive the Separation Benefits, I must sign and return this Release within 50 days of its presentation to me after my termination of employment;
3. I have carefully read and understand this Release;
4. The Company advised me to consult with an attorney and/or any other advisors of my choice before signing this Release;
5. I understand that this Release is LEGALLY BINDING and by signing it I give up certain rights;
6. I have voluntarily chosen to enter into this Release and have not been forced or pressured in any way to sign it;
7. I acknowledge and agree that the Separation Benefits are contingent on execution of this Release, which releases all of my claims against the Company and the Releasees, and I KNOWINGLY AND VOLUNTARILY AGREE TO RELEASE the Company and the Releasees from any and all claims I may have, known or unknown, in exchange for the benefits I have obtained by signing, and that these benefits are in addition to any benefit I would have otherwise received if I did not sign this Release;
8. I have seven (7) days after I sign this Release to revoke it by notifying the Company in writing. The Release will not become effective or enforceable until the seven (7) day revocation period has expired;
9. This Release includes a WAIVER OF ALL RIGHTS AND CLAIMS I may have under the Age Discrimination in Employment Act of 1967 (29 U.S.C. § 621 et seq.); and
10. This Release does not waive any rights or claims that may arise after this Release becomes effective, which is seven (7) days after I sign it, provided that I do not exercise my right to revoke this Release.
Intending to be legally bound, I have signed this Release as of the date written below.
| Signature: | Date Signed: |